A baseline transcriptomic signature predictive of clinical response to menin inhibitors in AML : The PRE-men retrosprospective Study
Vincent Alcazer(Lyon 1 Université), Maël Heiblig(Université Claude Bernard Lyon 1), Kaddour Chabane(Hospices Civils de Lyon), Anne-Marie Daull(Hospices Civils de Lyon), Pierre Sujobert(Université Claude Bernard Lyon 1), Sandrine Loron(Hôpital de la Croix-Rousse), Fiorenza Barraco(Hôpital Lyon Sud), Marie‐Virginie Larcher, Gaëlle Fossard(Hospices Civils de Lyon), Sandrine Hayette(Lyon 1 Université), Sophie Ducastelle-Leprêtre(Hospices Civils de Lyon), Marie Balsat(Hospices Civils de Lyon), Hélène Labussière-Wallet(Hôpital Lyon Sud), Zofia Gross(Hospices Civils de Lyon), Pauline Bertin-Mourot(Hôpital Lyon Sud), Juliette Helluin(Hôpital Lyon Sud), Lila Gilis(Hospices Civils de Lyon)
Cited by 0
Related Papers
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*
|British Journal of Dermatology|2021|414
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition
|Blood|2015|383
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309